These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16170225)

  • 1. Will pharmacogenomic discoveries improve HIV therapeutics?
    Haas DW
    Top HIV Med; 2005; 13(3):90-5. PubMed ID: 16170225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.
    Haas DW; Smeaton LM; Shafer RW; Robbins GK; Morse GD; Labbe L; Wilkinson GR; Clifford DB; D'Aquila RT; De Gruttola V; Pollard RB; Merigan TC; Hirsch MS; George AL; Donahue JP; Kim RB
    J Infect Dis; 2005 Dec; 192(11):1931-42. PubMed ID: 16267764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.
    Cressey TR; Lallemant M
    Infect Genet Evol; 2007 Mar; 7(2):333-42. PubMed ID: 17045554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of antiretrovirals.
    Tozzi V
    Antiviral Res; 2010 Jan; 85(1):190-200. PubMed ID: 19744523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of HIV therapy.
    Owen A; Pirmohamed M; Khoo SH; Back DJ
    Pharmacogenet Genomics; 2006 Oct; 16(10):693-703. PubMed ID: 17001288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.
    Motsinger AA; Ritchie MD; Shafer RW; Robbins GK; Morse GD; Labbe L; Wilkinson GR; Clifford DB; D'Aquila RT; Johnson VA; Pollard RB; Merigan TC; Hirsch MS; Donahue JP; Kim RB; Haas DW
    Pharmacogenet Genomics; 2006 Nov; 16(11):837-45. PubMed ID: 17047492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics and the potential for the individualization of antiretroviral therapy.
    Phillips EJ; Mallal SA
    Curr Opin Infect Dis; 2008 Feb; 21(1):16-24. PubMed ID: 18192781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.
    Michaud V; Bar-Magen T; Turgeon J; Flockhart D; Desta Z; Wainberg MA
    Pharmacol Rev; 2012 Jul; 64(3):803-33. PubMed ID: 22759796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.
    Martin AM; Nolan D; Gaudieri S; Phillips E; Mallal S
    Pharmacogenomics; 2004 Sep; 5(6):643-55. PubMed ID: 15335286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV pharmacogenomics: closer to personalized therapy?
    Payne DA; Bryant BJ;
    Am J Pharmacogenomics; 2004; 4(3):141-50. PubMed ID: 15174895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human genetic variability and HIV treatment response.
    Haas DW
    Curr HIV/AIDS Rep; 2006 Jul; 3(2):53-8. PubMed ID: 16608660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualising HIV treatment--pharmacogenetics and immunogenetics.
    Telenti A; Aubert V; Spertini F
    Lancet; 2002 Mar; 359(9308):722-3. PubMed ID: 11888578
    [No Abstract]   [Full Text] [Related]  

  • 14. Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.
    Jørgensen LB; Katzenstein TL; Gerstoft J; Mathiesen LR; Pedersen C; Nielsen C
    Antivir Ther; 2000 Sep; 5(3):187-94. PubMed ID: 11075938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacogenetics. Tailored therapy in medicine -- opportunities and challenges].
    Scharplatz M; Puhan M; Steurer J; Bachmann LM
    Praxis (Bern 1994); 2004 Mar; 93(10):359-65. PubMed ID: 15052854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacogenetics of antiretroviral therapy: a review of studies to date.
    Quirk E; McLeod H; Powderly W
    Clin Infect Dis; 2004 Jul; 39(1):98-106. PubMed ID: 15206060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?
    Nolan D; Gaudieri S; Mallal S
    J HIV Ther; 2003 May; 8(2):36-41. PubMed ID: 12838163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV pharmacogenetics in clinical practice: recent achievements and future challenges.
    Tozzi V; Libertone R; Liuzzi G
    Curr HIV Res; 2008 Nov; 6(6):544-54. PubMed ID: 18991620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
    J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.